Upon joining the study, an initial visit is conducted to confirm eligibility. This involves a thorough review of medical history and a physical examination.

Blood tests are performed to measure specific markers related to rheumatoid arthritis, such as ACPA levels and hsCRP levels. ACPA stands for anti-citrullinated protein antibodies, and hsCRP is high-sensitivity C-reactive protein, both of which are indicators of inflammation in the body.

Joint assessments are conducted to count the number of tender and swollen joints.

Participants receive the study medication, IMVT-1402, or a placebo. The placebo looks like the study medication but does not contain the active substance.

The medication is administered as a solution for injection under the skin, known as subcutaneous use.

The dosage and frequency of administration are determined by the study protocol and are explained during this period.

Regular follow-up visits are scheduled to monitor the response to the treatment and any side effects.

The effectiveness of the treatment is evaluated using the ACR20 response criteria, which measures a 20% improvement in tender and swollen joint counts, as well as other symptoms.

Participants who respond positively to the treatment continue to the next phase of the study.

Participants who continue in the study receive either the study medication or placebo, as per the study design.

The focus is on maintaining the response achieved in the first treatment period.

Regular assessments are conducted to monitor changes in disease activity using scores such as CDAI and SDAI, which are clinical and simplified disease activity indices.

At the end of the study period, a final evaluation is conducted to assess the overall response to the treatment.

Participants undergo a comprehensive review, including physical examinations and laboratory tests, to determine the long-term effects and safety of the treatment.